BioCentury | Jan 14, 2020
Finance

Tyra raises $50M series A for cancer drug resistance

...kinase inhibitors. Co-founder and COO Daniel Bensen was head of immunology and protein chemistry at Cidara Therapeutics Inc....
BioCentury | Sep 3, 2019
Company News

Sept. 3 Company Quick Takes: Mundipharma-Cidara, Roche-Spark, Vascepa

...Mundipharma licenses rights to Cidara’s rezafungin Cidara Therapeutics Inc. (NASDAQ:CDTX) granted Mundipharma International Ltd. (Dublin, Ireland) exclusive rights...
...CV events. BioCentury Staff rezafungin (CD101 IV, biafungin, sp 3025) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cidara Therapeutics Inc. Mundipharma...
BioCentury | Jul 31, 2019
Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

...CRISPR expects initial data from both studies this year. Candida therapy meets in Phase II Cidara Therapeutics Inc....
...mucin domain 3 BioCentury Staff KSI-301 rezafungin (CD101 IV, biafungin, sp 3025) Vumerity, diroximel fumarate (ALKS 8700, BIIB098) Alkermes plc Biogen Inc. Cidara Therapeutics Inc. Kodiak...
BioCentury | Apr 20, 2018
Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

...transplant is expected in 2019. Rezafungin is an IV formulation of biafungin, an echinocandin antifungal. Cidara Therapeutics Inc....
...Status: Phase II data Milestone: Start Phase III (mid-2018) Elizabeth S. Eaton rezafungin (CD101 IV, biafungin, sp 3025) Cidara Therapeutics Inc....
BioCentury | Mar 30, 2018
Finance

Bug money

...the preclinical pipelines of venture-backed companies whose lead indications are not bacterial infections. For instance, Cidara Therapeutics Inc....
...Appili Therapeutics Inc., Halifax, Nova Scotia Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Boston, Mass. Cidara Therapeutics Inc....
BioCentury | Jan 4, 2018
Company News

Management tracks: Acceleron, Selecta

...Wilson as CFO. He was VP of finance and accounting and chief accounting officer at Cidara Therapeutics Inc....
BioCentury | Apr 28, 2017
Finance

Hatching VC incubators

...2015, dates back to around 2013 when 5AM was incubating K2 Therapeutics Inc. K2 later became Cidara Therapeutics Inc....
...Dataset includes all disclosed companies founded since the incubators were officially were launched; consequently, 5AM’s Cidara Therapeutics Inc....
...La Jolla, Calif. Bay City Capital, San Francisco, Calif. Blueprint Medicines Corp. (NASDAQ:BPMC), Cambridge, Mass. Cidara Therapeutics Inc....
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...to existing antibiotics $84.7 million; $1.6 million plus $5.4 million in milestones Phase I 2012 Cidara Therapeutics Inc....
...of awards went to companies developing non-traditional antibiotics for Pseudomonas and other Gram-negative bacterial infections. Cidara Therapeutics Inc....
...NYSE:BMY), New York, N.Y. Cancer Research Institute, New York, N.Y. Cancer Research UK, London, U.K. Cidara Therapeutics Inc....
BioCentury | Apr 7, 2017
Finance

Fade to black

...Phase III SOLITAIRE-U trial to treat gonorrhea, and Cempra suspends development for non-alcoholic steatohepatitis (NASH) Cidara Therapeutics Inc....
BioCentury | Mar 30, 2017
Preclinical News

CARB-X reveals first investments

...The synthetic fluorocycline antibiotic against multidrug-resistant bacteria is in Phase I testing. Other recipients included Cidara Therapeutics Inc....
Items per page:
1 - 10 of 39
BioCentury | Jan 14, 2020
Finance

Tyra raises $50M series A for cancer drug resistance

...kinase inhibitors. Co-founder and COO Daniel Bensen was head of immunology and protein chemistry at Cidara Therapeutics Inc....
BioCentury | Sep 3, 2019
Company News

Sept. 3 Company Quick Takes: Mundipharma-Cidara, Roche-Spark, Vascepa

...Mundipharma licenses rights to Cidara’s rezafungin Cidara Therapeutics Inc. (NASDAQ:CDTX) granted Mundipharma International Ltd. (Dublin, Ireland) exclusive rights...
...CV events. BioCentury Staff rezafungin (CD101 IV, biafungin, sp 3025) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cidara Therapeutics Inc. Mundipharma...
BioCentury | Jul 31, 2019
Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

...CRISPR expects initial data from both studies this year. Candida therapy meets in Phase II Cidara Therapeutics Inc....
...mucin domain 3 BioCentury Staff KSI-301 rezafungin (CD101 IV, biafungin, sp 3025) Vumerity, diroximel fumarate (ALKS 8700, BIIB098) Alkermes plc Biogen Inc. Cidara Therapeutics Inc. Kodiak...
BioCentury | Apr 20, 2018
Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

...transplant is expected in 2019. Rezafungin is an IV formulation of biafungin, an echinocandin antifungal. Cidara Therapeutics Inc....
...Status: Phase II data Milestone: Start Phase III (mid-2018) Elizabeth S. Eaton rezafungin (CD101 IV, biafungin, sp 3025) Cidara Therapeutics Inc....
BioCentury | Mar 30, 2018
Finance

Bug money

...the preclinical pipelines of venture-backed companies whose lead indications are not bacterial infections. For instance, Cidara Therapeutics Inc....
...Appili Therapeutics Inc., Halifax, Nova Scotia Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Boston, Mass. Cidara Therapeutics Inc....
BioCentury | Jan 4, 2018
Company News

Management tracks: Acceleron, Selecta

...Wilson as CFO. He was VP of finance and accounting and chief accounting officer at Cidara Therapeutics Inc....
BioCentury | Apr 28, 2017
Finance

Hatching VC incubators

...2015, dates back to around 2013 when 5AM was incubating K2 Therapeutics Inc. K2 later became Cidara Therapeutics Inc....
...Dataset includes all disclosed companies founded since the incubators were officially were launched; consequently, 5AM’s Cidara Therapeutics Inc....
...La Jolla, Calif. Bay City Capital, San Francisco, Calif. Blueprint Medicines Corp. (NASDAQ:BPMC), Cambridge, Mass. Cidara Therapeutics Inc....
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...to existing antibiotics $84.7 million; $1.6 million plus $5.4 million in milestones Phase I 2012 Cidara Therapeutics Inc....
...of awards went to companies developing non-traditional antibiotics for Pseudomonas and other Gram-negative bacterial infections. Cidara Therapeutics Inc....
...NYSE:BMY), New York, N.Y. Cancer Research Institute, New York, N.Y. Cancer Research UK, London, U.K. Cidara Therapeutics Inc....
BioCentury | Apr 7, 2017
Finance

Fade to black

...Phase III SOLITAIRE-U trial to treat gonorrhea, and Cempra suspends development for non-alcoholic steatohepatitis (NASH) Cidara Therapeutics Inc....
BioCentury | Mar 30, 2017
Preclinical News

CARB-X reveals first investments

...The synthetic fluorocycline antibiotic against multidrug-resistant bacteria is in Phase I testing. Other recipients included Cidara Therapeutics Inc....
Items per page:
1 - 10 of 39